http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
CASE REPORT : A Case of Venlafaxine-Induced Interstitial Lung Disease
( Serim Oh ),( Seung Ick Cha ),( Hyera Kim ),( Min Jung Kim ),( Sun Ha Choi ),( Hye Won Seo ),( Tae In Park ) 대한결핵 및 호흡기학회 2014 Tuberculosis and Respiratory Diseases Vol.77 No.2
A patient treated with venlafaxine for major depression developed an interstitial lung disease (ILD) with the characteristic clinical, radiological and pathological features of chronic hypersensitivity pneumonitis. A high resolution computed tomography scan demonstrated ground glass opacity, mosaic perfusion with air-trapping and traction bronchiectasis in both lungs. The pathological findings were consistent with a nonspecific interstitial pneumonia pattern. Clinical and radiological improvements were noted after the discontinuation of venlafaxine and the administration of a corticosteroid. This report provides further evidence that the anti-depressant venlafaxine can cause ILD.
박나영(Nayoung Park),민세림(Serim Min),손영후(Young Hu Shon),남진현(Jin Hyun Nam),권순홍(Sun-Hong Kwon) 대한약학회 2021 약학회지 Vol.65 No.6
Unapproved investigational drugs have substantial uncertainty in terms of efficacy and safety. The compassionate use of investigational drugs, nevertheless, provides a patient with a serious disease or life-threatening condition a pathway to access unauthorized medications. This has gained significant traction during the Coronavirus 2019 disease pandemic. We review the laws and regulations of programs in the United States of America, Australia, the United Kingdom, and South Korea, where such programs are currently in effect, specifically on the following aspects: regulations, requirements, eligible patients, charges, and patient safety plans. Additionally, we investigated therapeutic-approval cases in South Korea from January 2016 to March 2021.
Kim, Hyera,Cha, Seung-Ick,Shin, Kyung-Min,Lim, Jae-Kwang,Oh, Serim,Kim, Min Jung,Lee, Yong Dae,Kim, Miyoung,Lee, Jaehee,Kim, Chang-Ho The Korean Academy of Tuberculosis and Respiratory 2014 Tuberculosis and Respiratory Diseases Vol.77 No.3
Background: Bronchial anthracofibrosis (BAF), which is associated with exposure to biomass smoke in inefficiently ventilated indoor areas, can take the form of obstructive lung disease. Patients with BAF can mimic or present with an exacerbation of chronic obstructive pulmonary disease (COPD). The purpose of the current study was to investigate the prevalence of BAF in Korean patients with COPD exacerbation as well as to examine the clinical features of these patients in order to determine its clinical relevance. Methods: A total of 206 patients with COPD exacerbation were divided into BAF and non-BAF groups, according to computed tomography findings. We compared both clinical and radiologic variables between the two groups. Results: Patients with BAF (51 [25%]) were older, with a preponderance of nonsmoking women; moreover, they showed a more frequent association with exposure to wood smoke compared to those without BAF. However, no differences in the severity of illness and clinical course between the two groups were observed. Patients in the BAF group had less severe airflow obstruction, but more common and severe pulmonary hypertension signs than those in the non-BAF group. Conclusion: Compared with non-BAF COPD, BAF may be associated with milder airflow limitation and more frequent signs of pulmonary hypertension with a more severe grade in patients presenting with COPD exacerbation.
Kim Hyun-Ki,Park Hyung-Doo,Lee Sang-Guk,Chae Hyojin,Song Sang Hoon,Lee Yong-Wha,Yun Yeo-Min,Ahn Sunhyun,Kim Serim,Lee Sun Min,Lee Soo-Youn,Chun Sail 대한진단검사의학회 2021 Annals of Laboratory Medicine Vol.41 No.3
Background: Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) is increasingly used for immunosuppressive drug tests. However, most LC-MS/MS tests are laboratory-developed and their agreement is unknown in different Korean laboratories. This interlaboratory comparison study evaluated test reproducibility and identified potential error sources. Methods: Test samples containing three concentrations of tacrolimus, sirolimus, everolimus, cyclosporine, and mycophenolic acid were prepared by pooling surplus samples from patients undergoing routine therapeutic drug monitoring and tested in duplicate in the participating 10 clinical laboratories. Reconstitution and storage experiments were conducted for the commonly used commercial calibrator set. The robust estimators of reproducibility parameters were calculated. Spearman’s rank correlation coefficient (rho, ρ) was used to evaluate the correlation between drugs. Multiple linear regression was used to determine whether the experimental conditions alter the calibration curves. Results: The reproducibility coefficient of variation exceeded 10% only for sirolimus concentrations 1 and 2 (10.8% and 12.5%, respectively) and everolimus concentrations 1 and 2 (12.3% and 11.4%, respectively). The percent difference values showed weak correlations between sirolimus and everolimus (ρ=0.334, P=0.175). The everolimus calibration curve slope was significantly altered after reconstitution following prolonged 5°C storage (P=0.015 for 14 days; P=0.025 for 28 days); the expected differences at 6 ng/mL were 0.598% for 14 days and 0.384% for 28 days. Conclusions: LC-MS/MS test reproducibility for immunosuppressive drugs seems to be good in the Korean clinical laboratories. Continuous efforts are required to achieve test standardization and harmonization, especially for sirolimus and everolimus.
A Case of Multicentric Castleman's Disease Presenting with Follicular Bronchiolitis
HwangBo, Yup,Cha, Seung-Ick,Lee, Yong Hoon,Lee, So Yeon,Seo, Hyewon,Oh, Serim,Kim, Minjung,Choi, Sun Ha,Park, Tae In,Shin, Kyung-Min The Korean Academy of Tuberculosis and Respiratory 2013 Tuberculosis and Respiratory Diseases Vol.74 No.1
Multicentric Castleman's disease (CD) is a rare atypical lymphoproliferative disorder, which is characterized by various systemic manifestations. Some patients with multicentric CD may have concomitant lung parenchymal lesions, for which lymphoid interstitial pneumonia (LIP) is known to be the most common pathologic finding. Follicular bronchiolitis and LIP are considered to be on the same spectrum of the disease. We describe a case of multicentric CD with pulmonary involvement, which was pathologically proven as follicular bronchiolitis.
Park Hae-Young,Kwon Jin-Won,Kim Hye-Lin,Kwon Sun-Hong,Nam Jin Hyun,Min Serim,Oh In-Sun,Bea Sungho,Choi Sun Ha 대한의학회 2023 Journal of Korean medical science Vol.38 No.21
Background: Regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB) have been changed from injectable-containing regimens to all-oral regimens. The economic effectiveness of new all-oral regimens compared with conventional injectable-containing regimens was scarcely evaluated. This study was conducted to compare the cost-effectiveness between all-oral longer-course regimens (the oral regimen group) and conventional injectablecontaining regimens (the control group) to treat newly diagnosed MDR-TB patients. Methods: A health economic analysis over lifetime horizon (20 years) from the perspective of the healthcare system in Korea was conducted. We developed a combined simulation model of a decision tree model (initial two years) and two Markov models (remaining 18 years, sixmonth cycle length) to calculate the incremental cost-effectiveness ratio (ICER) between the two groups. The transition probabilities and cost in each cycle were assumed based on the published data and the analysis of health big data that combined country-level claims data and TB registry in 2013–2018. Results: The oral regimen group was assumed to spend 20,778 USD more and lived 1.093 years or 1.056 quality-adjusted life year (QALY) longer than the control group. The ICER of the base case was calculated to be 19,007 USD/life year gained and 19,674 USD/QALY. The results of sensitivity analyses showed that base case results were very robust and stable, and the oral regimen was cost-effective with a 100% probability for a willingness to pay more than 21,250 USD/QALY. Conclusion: This study confirmed that the new all-oral longer regimens for the treatment of MDR-TB were cost-effective in replacing conventional injectable-containing regimens.